The work addresses a gap that has shaped the trajectory of genome engineering for more than a decade. Since the advent of programmable nucleases, researchers have been able to direct double-strand breaks to almost any chosen sequence, and cellular repair machinery can sometimes stitch in a new DNA cassette at the break site. But that approach leans on the cell’s own repair pathways, which are error-prone, unpredictable and often disabling to the very sequences scientists want to insert. Broken DNA is dangerous DNA, and cells treat integration events as injuries to be patched rather than as opportunities for precise reconstruction.

Prime editing, first described in 2019, took a fundamentally different route. Rather than cutting both strands of the DNA double helix, a prime editor pairs a Cas9 nickase — an engineered enzyme that cuts only one strand — with an engineered reverse transcriptase. The editing instructions are carried on a prime editing guide RNA, or pegRNA, which both locates the target site and encodes the new genetic information the reverse transcriptase should write into the nicked strand. Because the process avoids double-strand breaks and does not require an additional donor DNA template supplied in bulk, prime editing has proven remarkably clean for small substitutions, insertions and deletions.

Where prime editing has historically faltered, however, is scale. The reverse transcriptase copies a sequence encoded within the pegRNA itself, and practical constraints on RNA length, delivery and synthesis efficiency have limited the size of the DNA payload that a single prime-editing event can install. For applications in which a functional gene, a large regulatory element or a multi-kilobase cassette must be placed at a defined genomic address, the technology’s ceiling has been a persistent frustration. Complementary systems — including CRISPR-associated transposases and integrase-based platforms — can move larger cargoes, but they typically bring their own constraints on target-site selection, orientation and cargo compatibility.

The new study, led by researchers working at the interface of protein engineering and genome technology, tackles the size problem by rethinking how the donor DNA participates in the reaction. In the reported strategy, termed donor-directed annealing, the genetic cargo is carried on a separate donor molecule rather than being encoded within the pegRNA. The prime editor still performs its characteristic task of opening the target site and synthesizing an exposed stretch of new DNA on the nicked strand, but that newly synthesized sequence is designed to serve as a molecular landing pad. Once exposed, it is complementary to sequences at the end of the donor fragment, and the two single-stranded regions find each other and anneal, drawing the donor cargo into the editing site.

The elegance of the design lies in what happens next. Cellular DNA repair enzymes process the annealed intermediate, ligating the donor fragment into the genome through the natural resolution of the flap-like structure that the prime editor has created. Because the specificity of the event is dictated by sequence complementarity between the editor-generated overhang and the donor terminus, the cell is never asked to recognize a double-strand break or to improvise an end-joining reaction. The authors report that this mechanism allows fragments substantially larger than the payloads accessible to conventional prime editing to be incorporated at defined loci, with precision determined largely by the programmed overlap rather than by stochastic cellular repair.

From a biochemical standpoint, donor-directed annealing converts what has been an intramolecular copying reaction into a hybridization-guided assembly step. Conventional prime editing is, in essence, a controlled form of DNA synthesis: the pegRNA templates every base that the reverse transcriptase installs. The new method retains that templated synthesis for a short anchoring sequence but delegates the bulk of the payload to a separate donor, which can be produced synthetically or by standard cloning at lengths far beyond what a pegRNA can encode. The trade-off is that the donor and the pegRNA must be co-delivered and their sequences coordinated, but the payoff is a system in which cargo size is no longer bound to the physical limits of the guide RNA.

The practical implications extend across both research and therapeutic arenas. In basic biology, the ability to drop large regulatory modules, reporter constructs or engineered gene circuits into precise genomic contexts would simplify experiments that currently require laborious screening of random integration events. In medicine, many inherited disorders are caused by mutations in genes that are too large, too structurally complex or too mutationally diverse to be addressed base by base. Delivering a corrected copy of a gene, or a functional cDNA, into its native locus under the control of endogenous regulatory elements — rather than scattering it randomly through the genome as viral vector gene therapy does — remains the aspirational gold standard, and integration strategies of this kind are among the most credible paths toward it.

The reported system also speaks to a recurring theme in the genome-editing literature: the value of avoiding double-strand breaks altogether. Studies across multiple cell types have associated double-strand-break-based editing with p53 activation, chromosomal rearrangements and large unintended deletions, concerns that are particularly acute for ex vivo cell therapies and in vivo applications alike. By building integration on a nicking enzyme and sequence-programmed annealing rather than on blunt-ended break repair, the approach aligns with the field’s broader movement toward editing chemistries that leave the genome’s integrity machinery largely undisturbed.

As with any genome-engineering advance, several questions will shape how the technique matures. The efficiency of integration across different genomic loci, cell types and species will need systematic mapping; cargo lengths will have practical ceilings set by delivery vehicles rather than by chemistry; and off-target activity — a concern for any nuclease-fusion system — will require careful characterization at both the sequence and chromosomal level. The study’s authors report encouraging precision at the sites they examined, and the strategy’s dependence on designed sequence complementarity offers a built-in specificity checkpoint that many integration methods lack. Independent replication and optimization in therapeutically relevant primary cells will be the next milestones.

What the work illustrates most clearly is how quickly the conceptual boundaries of genome editing continue to move. In barely a decade, the field has progressed from cutting DNA at chosen addresses, to rewriting individual letters of the genetic code, to contemplating the programmed installation of whole functional modules at will. Donor-directed annealing extends prime editing’s core strengths — precision, minimized DNA damage and programmability — into a size regime that those strengths had not previously reached. If the method’s efficiency and reliability hold up as it is tested more broadly, large-fragment insertion could shift from a heroic, low-yield exercise to a routine operation in the genome engineer’s toolkit, with consequences for drug discovery, synthetic biology and, ultimately, the treatment of diseases that small edits alone cannot fix.

Subject of Research: Precise integration of large DNA fragments into genomic target sites using prime editing with donor-directed annealing

Article Title: Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing

Article References: Jung, H., Jeong, B., Kim, Y.-W., Jung, C., Lee, S., Uhm, H., Kim, H., Oh, Y. E., Park, Y., Lee, Y., Kang, M., Im, H. W., Kim, D., Lee, S., Kim, Y., Choi, K., & Bae, S. (2026). Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03301-2

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03301-2

Keywords: prime editing, genome editing, CRISPR, gene therapy, DNA integration, pegRNA, reverse transcriptase, Cas9 nickase, large DNA fragments, donor-directed annealing, biotechnology, genetic engineering

Prime editing is often described as a molecular search-and-replace system. It couples a catalytically impaired Cas9 nickase to an engineered reverse transcriptase, and it is programmed by a prime editing guide RNA, or pegRNA, which both locates the genomic target and carries the template encoding the desired edit. Because the method writes new genetic information without making a double-strand break in the DNA and without requiring an external donor template, it has long been viewed as one of the most versatile tools in the genome editing repertoire, capable of installing all twelve possible base-to-base conversions as well as small insertions and deletions. Yet translating that versatility into animals, and ultimately patients, has proved difficult. The prime editor protein is far too large to fit inside a single adeno-associated virus vector, forcing researchers to rely on cumbersome dual-vector systems, while concerns about the long-term expression of an editor in a patient’s tissues have made viral delivery unattractive for clinical development.

Non-viral delivery offers a way around those concerns. Lipid nanoparticles, the same technology that carried mRNA vaccines into billions of arms, can deliver the prime editor in transient mRNA form together with its pegRNA, giving the editor a brief window of activity before it is degraded by the cell. The problem has been efficiency. Earlier attempts to deliver prime editing systemically with lipid nanoparticles produced editing levels far below what would be needed clinically, required repeated injections, or depended on doses of RNA so high that they exceeded what regulators would consider translatable. The fragile nature of long RNA molecules inside the bloodstream and inside cells is a central culprit: unmodified or lightly modified pegRNAs are rapidly chewed apart by nucleases, and even end modifications at the RNA termini, the standard protective measure borrowed from antisense oligonucleotide chemistry, leave long internal stretches of the guide exposed and vulnerable.

The Wuhan-led team’s solution was to extend chemical protection far beyond the ends of the guide RNA. Rather than modifying only the terminal nucleotides, the researchers densely incorporated modified RNA motifs throughout both the fixed regions of the pegRNA, such as the scaffold and the engineered extension motifs like evopreQ1, and the variable regions, including the spacer, the reverse transcriptase template, and the primer binding site. The chemical toolkit relied on well-established modifications from the RNA therapeutics field, principally 2′-O-methyl groups on the ribose sugar and phosphorothioate linkages in the phosphate backbone, both of which are known to shield RNA from nuclease degradation and, in the case of 2′-O-methyl groups, to subtly alter pairing geometry and affinity. The team describes the resulting molecules as super-end-modified RNAs, in which terminal protection and dense internal modification act in combination.

The optimization was systematic. In human cell experiments using electroporated prime editor mRNA, the researchers tested modification patterns in each structural element of the pegRNA in turn, measuring editing outcomes at endogenous loci such as EMX1, where the system installed a three-base deletion, and HEK3, where it installed a single-base insertion. They varied the density of 2′-O-methyl and phosphorothioate modifications at the 5′ end of the spacer, in the primer binding site, in the reverse transcriptase template, and in the extended scaffold motifs, and then combined the best-performing patterns. Analyses of editing byproducts showed that the dense modifications did not increase the proportion of indels or unwanted scaffold-insertion events relative to total editing, and cell viability assays indicated the heavily modified guides were not toxic to the treated cells, an important consideration since excessive chemical modification of guide RNAs has previously been associated with cellular stress.

The in vivo results were the centerpiece. Using lipid nanoparticles to co-deliver prime editor mRNA and the densely modified pegRNA into mice, the team achieved nearly 70 percent prime editing efficiency in the bulk liver, a level indicating that most hepatocytes in the organ had been edited. Perhaps more consequential for clinical translation, a single injection at a lipid nanoparticle dose the authors describe as clinically translatable was sufficient to suppress the expression of the target protein in vivo, and under those dose conditions the densely modified guide produced an approximately 80-fold increase in editing efficiency compared with conventional end-modified pegRNAs. Toxicity assessments, including serum liver enzyme measurements and analysis of editing byproducts, supported the tolerability of the approach, and off-target analyses at predicted sites suggested the chemical modifications did not worsen targeting fidelity.

The generality of the strategy proved equally important. The dense motif modification approach was not confined to prime editing. When the team applied the same modification logic to guide RNAs carrying the widely used MS2 RNA motif, which is exploited in RNA-guided recruitment platforms such as base editor systems that tether an editor protein to a Cas9 nickase through an RNA aptamer interaction, they saw broad improvements across multiple RNA sequences and split RNA-guided genome editing platforms, with base editing efficiencies rising by up to 11-fold. The researchers also combined the modified guides with mRNA encoding ancillary factors known to boost prime editing, such as MLH1-domain constructs, and observed further gains in vivo, indicating that RNA chemistry and protein engineering enhancements can be layered rather than traded off against one another.

The findings arrive at a moment when the field is converging on transient, non-viral delivery as the safest route to in vivo genome editing. Clinical programs using lipid nanoparticle delivery of CRISPR-Cas9 mRNA and guide RNA have already demonstrated that single-dose in vivo gene knockout is feasible in humans, and prime editing has shown curative promise in ex vivo settings such as engineered hematopoietic stem cells for sickle cell disease. What has lagged is in vivo precision editing, where the required correction must be installed in a large fraction of target tissue cells rather than simply disrupting a gene. By raising editing yields at clinically plausible doses, the dense modification strategy narrows the gap between what prime editing can do in a dish and what it can do in a body, and because the modifications are applied to the RNA guide rather than to the editor protein, they can in principle be adopted without redesigning the editing enzymes themselves.

Challenges remain before such a system could reach patients, including extending the approach beyond the liver, where lipid nanoparticles naturally accumulate, to other tissues, scaling the manufacture of long, densely modified pegRNAs under clinical quality standards, and confirming long-term safety in larger animal models. The authors note that the methodology builds on their earlier work developing rapid methods for generating long chemically modified pegRNAs, and patent applications on the pegRNA modifications have been filed through Wuhan University. Still, the study offers a concrete, generalizable recipe: protect the guide RNA densely, deliver the editor transiently, and let chemistry do much of the work that delivery vehicles alone could not. If the efficiency gains hold across tissues and disease targets, the modest RNA molecule at the heart of prime editing may prove to be the lever that finally lifts the technology from laboratory promise toward therapeutic reality.

Subject of Research: Engineered prime editing guide RNAs with densely modified RNA motifs for robust in vivo genome editing

Article Title: Dense RNA motif modifications enable robust in vivo prime editing and enhance efficiencies of diverse editing systems

Article References: Lei, X., Chen, D., Zhang, K., Liu, X., Chen, Q., Zhang, Y., Ji, R., Zhu, J., Zhang, Q., Zhang, Y., & Yin, H. (2026). Dense RNA motif modifications enable robust in vivo prime editing and enhance efficiencies of diverse editing systems. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-026-01787-4

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01787-4

Keywords: prime editing, pegRNA, chemical modification, lipid nanoparticles, in vivo genome editing, base editing, RNA therapeutics, gene therapy, 2'-O-methyl, phosphorothioate, mouse liver, non-viral delivery